In this conversation, Stephen Harrison and Mazen focus on how treatment guidelines and therapeutic choices might vary for patients starting at F2 vs. F3 vs. compensated (maybe even decompensated?) cirrhosis. One key issue is “de-escalation” — whether guidelines will suggest treating with agents that are more potent injectible anti-fibrotics for later stage patients, then retreating to orals with broader metabolic effects when patients’ fibrosis has regressed to F2 or F1. The subject of “backbone therapy” comes up for the first time here, although it will be in later conversations of this episode as well. Louise Campbell and Roger Green round out the conversation with questions and observations. There is a lot to unpack here, so listen, learn and enjoy.
TOPICS: 89bio, Akero Therapeutics, aldafermin, cirrhosis, efruxifermin, FGF-21, Fibrosis Level 3, Fibrosis Level 4, Intercept Pharmaceuticals, inventiva, lanifibranor, Lean NASH, Madrigal, NAFLD, NASH, NGM Biopharmaceuticals, Novo Nordisk, obeticholic acid, Phase3, Semaglutide, resmetirom, backbone therapy, Type 2 diabetes, FGF-19, de-escalating therapy, combination therapy
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast